Ireland
--:--IST
Latest
Clinical Trials in France / NCT07630298
Starting soon Not applicable

A Comparative Study of Driving Performance Among Adolescents With Autism Spectrum Disorder and Neurotypical Adolescents

NCT07630298 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-06-17

Condition(s) studied

Autism Spectrum Disorders

Investigational drug(s) / intervention(s)

Assessment of executive functions and attentionEvaluation on a driving simulatorEvaluation on-road

Assessment of executive functions and attention: * Attention Assessment Test (TAP), * Trail Making Test (TMT), which assesses mental flexibility, * Stroop Selective Attention Test, assessing the ability to inhibit automatic processes, * Wisconsin Card Sorting Test (WSCT-modified), assessing abstract reasoning and the ability to change cognitive strategies in response to changes in the environment.

Evaluation on a driving simulator: The 1-hour simulator assessment will be preceded by a 1.5-hour orientation session. The simulator used is the Rehab Evolution, manufactured by Develter Innovation.

Evaluation on-road: The on-road evaluation will be conducted using a dual-control vehicle, with a certified driving instructor and an occupational therapist. The evaluation will last one hour.

Study summary

The primary objective of this study is to compare the number of driving errors made by novice adolescents (0-5 hours of driving instruction) with ASD to those made by neurotypical adolescents during a standardized driving simulator assessment. The secondary objectives of the study are to:

* Compare the visual strategies used by adolescents with ASD to those of neurotypical adolescents during a driving assessment on a simulator.
* Compare the types of errors and driving performance (i.e., speed, reaction time, following distance, and braking distance) of adolescents with ASD to those of neurotypical adolescents during the driving simulator assessment.
* Compare the driving performance of these two groups during a real-world road assessment using the TRIP scale.
* Examine the consistency between driving performance measured in the simulator and that observed in real-world conditions for both groups.
* Compare the anxiety levels of these two groups during driving tests on the simulator and on the road.

Eligibility

Sex
ALL
Min age
15 Years
Max age
17 Years
Healthy volunteers
Accepted
Inclusion Criteria: ASD Group * Adolescents aged 15 to 17, * With a confirmed diagnosis of ASD by a physician, * Without an intellectual disability, with a Fluid Reasoning Index (IRF) greater than 80, * Who have passed the written driver's license exam, * With no or very limited driving experience (\<5 hours), * Enrolled in the social security system. Neurotypical group: * Adolescents aged 15 to 17, * Without a diagnosis of neurodevelopmental disorders or learning disabilities, * With a standard educational background, * Who have passed the written driver's license exam, * With no or very limited driving experience (\<5 hours), * Enrolled in the social security system. Exclusion Criteria: * Adolescents with ADHD (attention-deficit/hyperactivity disorder) and/or ODD (oppositional defiant disorder) and/or IDD (intellectual disability) and/or SLI (specific language impairment) with associated comprehension difficulties, * Adolescents who already have a driver's license, * Adolescents currently taking driving lessons and/or with more than 5 hours of driving experience, * Adolescents who have suffered a head injury during childhood, * Other serious medical conditions that may interfere with participation in the sessions, * Participation in another research protocol.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hôpital La Musse Saint-Sébastien-de-Morsent France

More Hopital La Musse trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07630298 on ClinicalTrials.gov ↗ ← All trials in France